Systemic Inflammation Response Index as a Prognostic Marker in Cancer Patients: A Systematic Review and Meta-Analysis of 38 Cohorts

• Published in: Dose-response Vol. 19; no. 4; p. 15593258211064744
• Main Authors: Zhou, Qian, Su, Si, You, Wen, Wang, Tao, Ren, Tong, Zhu, Lan
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-10-2021; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Cancer; Medical prognosis; Meta-analysis; Original; meta-analysis; systemic inflammation response index; cancer; biomarker; prognosis
• ISSN: 1559-3258; 1559-3258
• DOI: 10.1177/15593258211064744

Background
The systemic inflammation response index (SIRI), a novel and cost-effective serum biomarker, is associated with prognosis in patients with cancer. However, the prognostic value of the SIRI in cancer remains unclear. This study aimed to evaluate the potential role of the SIRI as a prognostic indicator in cancer.
Methods
Reports in which the prognostic value of the SIRI in cancer was evaluated were retrieved from electronic databases. The pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to evaluate the prognostic significance of the SIRI. The odds ratio (OR) was also calculated to explore the association between the SIRI and clinicopathological features.
Results
This study included 30 retrospective studies with 38 cohorts and 10 754 cases. The meta-analysis indicated that a high SIRI was associated with short overall survival (OS) (HR = 2.04, 95% CI = 1.82–2.29, P < .001) and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS) (HR = 2.08, 95% CI = 1.84–2.34, P < .001). Subgroup analysis showed that the prognostic value of the SIRI was significant in all kinds of cancer included. Moreover, the SIRI was significantly correlated with sex, tumor size, T stage, N stage, TNM stage, and lymphovascular invasion.
Conclusion
The pretreatment SIRI could be a promising universal prognostic indicator in cancer.